Rasagiline (Azilect®) is a novel, selective, irreversible second-generation inhibitor of monoamine
oxidase type B (MAO-B). It is administered orally once daily and is approved in the US, …

… taking placebo received rasagiline, 2 … rasagiline resulted in better functional status at 1 year
when all participants were receiving active treatment and the symptomatic effect of rasagiline …

… , rasagiline is biotransformed to aminoindan, a non‐amphetamine compound. Rasagiline is
… Thus, in addition to symptomatic benefits, rasagiline offers the promise of clinically relevant …

… Novel findings demonstrated that the major metabolite of rasagiline, 1-(R)-aminoindan …
rasagiline. This paper will review the earlier and present studies in the development of rasagiline …

… the possibility that rasagiline has disease-… receive rasagiline (at a dose of either 1 mg or 2
mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline …

… , 4 The potential of rasagiline to modify the progression of … rasagiline from a potential
disease-modifying effect.5-7 At the approved 1-mg daily dose, those patients treated with rasagiline …

… dosages of rasagiline, when the true effect of 2 mg of rasagiline corresponds to a 3-unit
improvement relative to placebo and the effect of 1 mg of rasagiline is between 0 and 3 units. …

… induced by rasagiline, its derivatives, … rasagiline, we have thus developed neuroprotective
anti-Alzheimer drugs (ladostigil [TV3326] and TV3279) from the pharmacophore of rasagiline. …

… with deprenyl or rasagiline. The doses of clorgyline, deprenyl and rasagiline used in this
study caused selective inhibition of MAOA (clorgyline) or MAO-B (deprenyl, rasagiline) with less …

… ▴ Rasagiline also possesses neuroprotective properties that are independent of its MAO
inhibitory activity. Unlike selegiline, rasagiline … ▴ Rasagiline has shown significant beneficial …